Release of Nonmuscle Myosin II from the Cytosolic Domain of Tumor Necrosis Factor Receptor 2 Is Required for Target Gene Expression
Unni M. Chandrasekharan, Lisa Dechert, Uchechukwu I. Davidson, Matthew Waitkus, Lori Mavrakis, Katherine Lyons, Jordan R. Beach, Xiaoxia Li, Thomas T. Egelhoff, Paul L. Fox, Paul E. DiCorleto*
*Corresponding author. E-mail:
This PDF file includes:
- Fig. S1. Amino acid sequences of myosin subunits coprecipitated with p75 cytosolic tail.
- Fig. S2. Residual myosin or p75 in cell lysates after sequential immunoprecipitations.
- Fig. S3. Specificity of the antibody used to immunoprecipitate ROCK1.
- Fig. S4. MRLC isoforms in endothelial cells.
- Fig. S5. Light microscopic imaging of endothelial cells deficient in MRLCs.
- Fig. S6. Abundance of reconstituted p75 and its deletion mutants.
- Fig. S7. The binding of TRAF2 to endogenous p75.
- Fig. S8. Western blotting analysis of the input sample used in measuring the kinetics of myosin and TRAF2 binding.
- Fig. S9. Coimmunoprecipitation of MHC IIA with p75.
- Fig. S10. Blebbistatin does not block the interaction between p75 and myosin.
Format: Adobe Acrobat PDF
Size: 6.16 MB
Citation: U. M. Chandrasekharan, L. Dechert, U. I. Davidson, M. Waitkus, L. Mavrakis, K. Lyons, J. R. Beach, X. Li, T. T. Egelhoff, P. L. Fox, P. E. DiCorleto, Release of Nonmuscle Myosin II from the Cytosolic Domain of Tumor Necrosis Factor Receptor 2 Is Required for Target Gene Expression. Sci. Signal. 6, ra60 (2013).